Heron Therapeutics Accused of Misleading Investors

Discussion in 'Heron Therapeutics' started by anonymous, Jun 7, 2019 at 12:50 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    15 firms fishing for investors for class action lawsuits. Looks like a few have actually recruited lead plaintiffs. LOVE IT! With the BS article that SR (HR) posted about the 'collaboration' in R&D at Heron, and living with the dysfunction at this place, maybe Tang will figure out (DOUBTFUL) that he has crappy leader selection (BQ, and a-hole RR already gone).

    According to the complaint, in October 2018, Heron announced the submission of its New Drug Application ("NDA") for HTX-011 to the U.S. Food and Drug Administration ("FDA") for post-operative pain management. It touted the data it used to support the filing. Heron's CEO went further by promoting Heron's prior experience with filing NDAs, as well as its close working relationship with the FDA. However, Heron failed to disclose that the HTX-011 NDA did not contain adequate information. In May 2019, Heron revealed that HTX-011 had failed to gain FDA approval because it lacked sufficient information. Specifically, the FDA denied HTX-011's NDA purely based on Heron's failure to include the requisite CMC and non-clinical information. On this news, Heron's stock price fell over 18% to close at $17.75 per share on May 1, 2019, and has yet to recover.
     

  2. anonymous

    anonymous Guest

    Unfortunately, the opportunity is now a bust. I was going to join but have decided to go another route.
     
  3. anonymous

    anonymous Guest

    The class action lawyer hacks are lining up to crap all over our executives. I want a ringside seat to watch!!
     
  4. anonymous

    anonymous Guest

    While I greatly hate ambulance chasing lawyers, Heron management deserves this. How in God’s name did they leave out the CMC data? Haven’t any of them done this before?
     
  5. anonymous

    anonymous Guest

    When CRL was announced Barry sounded like a crybaby victim and basically stated we could have provided all the data the FDA wanted on the spot if they only bothered to ask us. As if it was sitting in the file cabinet already. Now we’re saying approval by 1st HALF of 2020 which is ANOTHER YEAR and that is assuming a 6 mo review, so clearly he lied the first time and did/is misleading investors. No credibility.
     
  6. anonymous

    anonymous Guest

    The only news headlines for HRTX on Yahoo Finance are the attorneys seeking to find lead plaintiffs and additional plaintiffs for the class action lawsuits - can only hope...

    Separately, Barry (and others here) are moronic when they state that the FDA didn't tell us what we needed to include in the filing for 011. Please, any decent regulatory affairs leader would be completely in tune with what missing data would screw up the FDAs response.

    Lastly, JH quitting (not too bad of a thing...his 2 rehab stints weren't successful...), RS quitting (following JH...WTF?!?...I thought he was smarter than that), and RG quitting (nicest man alive, no backbone though, also following JH). News on the street is that our dear old moron RR is an equity investor in some pot company that they are going to. Should work well for JH.
     
  7. anonymous

    anonymous Guest

    Yeah, when are you idiots going to refile?
     
  8. anonymous

    anonymous Guest

    Yeah, this company is a bit of a joke from a management execution standpoint. CRLs Md year long delays is our middle name. We should be eating Pacira’s lunch but instead Barry is making excuses. 011 may be better product but Pacira management is clearly better than ours.
     
  9. anonymous

    anonymous Guest

     
  10. anonymous

    anonymous Guest

    Now it is 2020
     
  11. anonymous

    anonymous Guest

    To file or for approval?
     
  12. anonymous

    anonymous Guest

    Agree, all B and C players.
     
  13. anonymous

    anonymous Guest

    im still trying to figure out how/why we hired a medical director who lost their license for inappropriate contact with patients while under sedation?
     
  14. anonymous

    anonymous Guest

    HR asleep at the wheel
     
  15. anonymous

    anonymous Guest

    Hey F-ups, when are going to meet with FDA? Barry said CRL was FDA’s fault so shouldn’t you at least have met and refilled by now?
     
  16. anonymous

    anonymous Guest

    Everything is one big fire drill here right now. No one has a clue what they are doing. They messed up the first crack at this application and are realizing they are so far behind in getting what they need. Disaster. Don't be surprised if its a long delay. Feel bad for the reps who signed contingent offers, only to be blindsided by this stupidity. I just hope HR isn't lying to these same folks and saying oh no big deal the drug will launch next spring and all will be fine. It's not fine, trust me!
     
  17. anonymous

    anonymous Guest

    HR is a joke. SR liar. NC idiot. These people can't get out of their own way.
    Feel bad for those new hires. Sorry, you got jobbed.
     
  18. anonymous

    anonymous Guest

    Entire leadership team is and always has been second rate, which is why we’re always tripping over our own feet. It’s embarrassing.
     
  19. anonymous

    anonymous Guest

    Hey fcksticks, what bad news are you going to drop on your investors next week?
     
  20. anonymous

    anonymous Guest

    No news is bad news for this company. Maybe they’re all on summer break.